Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007-2013

Abstract

Background and ObjectivesJoint National Committee guidelines attempt to vary treatment recommendations for patients based on considerations of their comorbidities. The aim of the present study is to estimate the age-standardized prevalence of common comorbidities among Korean hypertension patients.Subjects and MethodsWe analyzed the Korea National Health and Nutrition Examination Survey from 2007 to 2013. Among the 58423 participants, 30092 adults, aged ≥30 yrs who completed a health examination and interview survey, were selected. The survey procedures were used to estimate weighted prevalence and odds ratios for 8 comorbidities, including obesity, diabetes mellitus, dyslipidemia, cardiovascular disease, chronic kidney disease, and thyroid disease.ResultsMost chronic conditions were more prevalent in adults with hypertension than in those without hypertension. Common comorbidities were obesity (60.1%), dyslipidemia (57.6%), and impaired fasting glucose (45.1%). Hypertensive patients with two or more comorbid diseases were 42.2% and those with three or more diseases were 17.7%. The age- and sex-specific prevalence of three or more comorbid diseases among male hypertension patients was significantly higher than those patients in the 30-59 (p<0.05) age group.ConclusionComorbidity is highly prevalent in Korean patients with hypertension.

Hypertension is the underlying cause of death assessed at the autopsy of individuals

“…In Brazil, the prevalence of diabetes in a multicenter study was 19.7%; and 50.4% of this was not previously diagnosed and 79.1% presented intermediate hyperglycemia, showing the serious problem of the disease in the country (26) . Regarding the other comorbidities that were identified, the findings were similar to those of the study that showed that hypertensive patients had a higher prevalence of dyslipidemia, chronic kidney disease, obesity, diabetes and cardiovascular diseases, including stroke, acute myocardial infarction and angina (27) . The presence of multimorbidities in hypertensive individuals may contribute to potential complications for increased mortality.…”

“…Resultados: A prevalência de hipertensão arterial foi de 66,2% e foi a segunda causa básica de óbito (25,6%) identificada na autópsia, precedida de aterosclerose (37,8%). As variáveis associadas à hipertensão foram: gênero feminino (OR = 2,30(1,90); ter um parceiro [OR = 0,55 (0,32-0,92)]; índice de massa corporal [OR = 1,14 (1,08-1,22)] e história de diabetes [OR = 2,39(1,27)]. Conclusão: A prevalência de hipertensão foi elevada e representou a segunda causa básica de óbito mais frequente.…”

Rho‐associated protein kinases as therapeutic targets for both vascular and parenchymal pathologies in Alzheimer's disease

“…Several population studies have shown that chronic hypertension during midlife (between ages of 35 and 64) increases the risk for developing AD later in life (Launer et al 2000;Feldstein 2012). Midlife hypertension as an independent risk factor may account for up to 8% of all cases of late-onset AD (Barnes and Yaffe 2011) and since hypertension is often comorbid with other risk factors such as obesity and hypercholesterolemia (Noh et al 2016), the cumulative contribution of hypertension to AD is much higher. The mechanism by which midlife hypertension may result in dementia likely stems from the irreversible alterations to the vasculature induced by high blood pressure.…”

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

“…[1][2][3] Furthermore, hypertension and dyslipidemia act synergistically to accelerate CVD progression, 4 and more than one half of patients with hypertension have dyslipidemia. 5,6 Many studies have also shown a positive correlation between blood cholesterol levels and CVD; thus, a reduction in cholesterol levels can significantly reduce the CVD risk. 7 Therefore, the goal of hypertension management is no longer blood pressure (BP) control alone but attenuation of overall CVD risk.…”